EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
Advertisement
EyeTechCare SA announced the completion of a EUR 7.5 million funding round. The funds were provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders. Aelios Finance and MAGS acted as advisers to the company, while Morgan Lewis acted for the investors.
“We were favourably impressed by the EyeTechCare team, whose innovative medical device should fill a major therapeutic void in the treatment of glaucoma and could prove a real technological breakthrough in overcoming this disease,” said SHAM’s head of investments, Olivier Szymkowiak. SHAM subscribed EUR 3 million to the financing.
Crédit Agricole Private Equity provided the balance of EUR 4.5 million. “We have been following EyeTechCare’s development since it was founded in July 2008, when we first invested in the company,” said Alexia Perouse, partner at Credit Agricole Private Equity. “What its management has succeeded in doing in less than two years convinced us of the company’s potential. We believe that EyeTechCare will succeed in bringing this new therapy for glaucoma to the world market within the next three years, which will bring a major change in the treatment of this disease.”
In its first funding round in July 2008, EyeTechCare raised EUR 1.2 million from Credit Agricole Private Equity and CEA-Investissement, which enabled it to complete preclinical studies of its device for the treatment of glaucoma. The funds raised in this second financing will be used to complete the first clinical trial in man, as well as establish the manufacturing facilities and the sales and marketing force required for this first product, whose market launch is scheduled for early 2011.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs
Parkinson’s researchers test a new approach against motor disorders
New virus drug will have to shoot at moving targets
New research may lead to improved diagnosis of autism
BioGaia initiates investigative study in type 2 diabetics
Viruses flourish in guts of healthy babies
Amorfix Life Sciences and Biogen Idec to collaborate on research for ALS disease
